Physician profile
John N Daniel
NPI 1083788160
$9,325.29
in general payments reported to CMS, 2019-2025
37 companies · $3,325 in 2025
The $3,325 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $55.99 · 2021: $368 · 2022: $968 · 2023: $1,759 · 2024: $2,643 · 2025: $3,325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,248 · Education: $328 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,248.43 |
| Education | $328.42 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,461.64 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Axsome Therapeutics, INC. | $779.08 | 2024-2025 | Sunosi |
| Jazz Pharmaceuticals INC. | $743.91 | 2019-2025 | |
| Novo Nordisk INC | $685.49 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $664.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Harmony Biosciences LLC | $540.15 | 2020-2025 | Wakix |
| Lundbeck LLC | $390.42 | 2022-2025 | Rexulti |
| Amgen INC. | $386.76 | 2019-2025 | Otezla, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $302.84 | 2022-2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $285.67 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $281.69 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $234.48 | 2020-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.93 | 2019-2025 | Jardiance |
| Corcept Therapeutics | $197.39 | 2025 | Korlym |
| Abbott Laboratories | $148.70 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.